Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

PGxPHGKB

Specific PHGKB|Pharmacogenomics PHGKB|Public Health Genomics and Precision Health Knowledge Base (PHGKB)
Effective August 1, 2024, this database will be discontinued. All content will remain searchable and be preserved online for historical purposes only until 2029.

Last Posted: Jun 27, 2024
spot light Spotlight

Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease
(Posted May 30, 2024 0PM)

From the article: "The increasingly widespread availability of genomic sequencing has enabled the identification of persons and families with uniquely favorable traits, including a very low incidence of clinical events. Such exceptional persons across diverse communities are playing an important role in the genesis of medicines for common cardiovascular diseases. "

Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid Leukemia
(Posted May 18, 2024 4PM)

From the abstract: " Can tailoring the intensity of induction therapy mitigate racial disparities in the outcome of pediatric patients with acute myeloid leukemia (AML)? Findings: In this comparative effectiveness analysis of 86 Black and 359 White patients with AML, Black patients exhibited a higher prevalence of low cytarabine pharmacogenomic 10–single-nucleotide variant (ACS10) scores, which were associated with an unfavorable outcome after initial treatment with low-dose cytarabine-based induction therapy. Augmentation of induction therapy was associated with improved outcome for patients with low ACS10 scores and with no disparity in outcome between Black patients and White patients."

Healthcare utilization and behavior changes following workplace genetic testing at a large U.S. healthcare system
(Posted May 08, 2024 11AM)

From the abstract: " This study explored employee health behavior changes and healthcare utilization following workplace genetic testing (wGT). Wellness program-associated wGT seeks to improve employee health, but related health implications are unknown. Methods: Employees of a large U.S. healthcare system offering wGT (cancer, heart disease, and pharmacogenomics - PGx) were sent electronic surveys. Self-reported data from those who received test results were analyzed. Descriptive statistics characterized responses, while logistic regression analyses explored correlates of responses to wGT."

Precision Medicine—Are We There Yet? A Narrative Review of Precision Medicine’s Applicability in Primary Care
W Evans et al, JPM, April 15, 2024 (Posted Apr 15, 2024 2PM)

From the abstract: "Precision medicine (PM) has the potential to transform an individual’s health, moving from population-based disease prevention to more personalised management. There is however a tension between the two, with a real risk that this will exacerbate health inequalities and divert funds and attention from basic healthcare requirements leading to worse health outcomes for many. All areas of medicine should consider how this will affect their practice, with PM now strongly encouraged and supported by government initiatives and research funding. In this review, we discuss examples of PM in current practice and its emerging applications in primary care, such as clinical prediction tools that incorporate genomic markers and pharmacogenomic testing. "


news Latest News and Publications
Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US. External Web Site Icon
Junjie Pan et al. Sci Rep 2024 14(1) 13935
Familial hypercholesterolemia care by Dutch pediatricians-mind the gaps. External Web Site Icon
Sibbeliene E van den Bosch et al. Eur J Pediatr 2024
Molecular identification of HLA-B75 serotype markers by qPCR: A more inclusive pharmacogenetic approach before carbamazepine prescription. External Web Site Icon
Kanoot Jaruthamsophon et al. Clin Transl Sci 2024 17(6) e13867
Pharmacogenetic testing in primary care could bolster depression treatment: A value proposition. External Web Site Icon
Nina R Sperber et al. Clin Transl Sci 2024 17(6) e13837
5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC. External Web Site Icon
Vamsidhar Velcheti et al. Clin Lung Cancer 2024
CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention. External Web Site Icon
Kayla R Tunehag et al. J Am Heart Assoc 2024 e033791
Pharmacogenomic Characterization of Childbearing-Aged Individuals With Mood Disorders in a Tertiary Care Perinatal Mental Health Clinic. External Web Site Icon
Jessica L W Mayer et al. J Clin Psychiatry 2024 85(2)
Rationale and design for a pragmatic randomized trial to assess gene-based prescribing for SSRIs in the treatment of depression. External Web Site Icon
Lindsay J Hines et al. Clin Transl Sci 2024 17(6) e13822
Pharmacogenomic insights in psychiatric care: uncovering novel actionability, allele-specific CYP2D6 copy number variation, and phenoconversion in 15,000 patients. External Web Site Icon
Jai N Patel et al. Mol Psychiatry 2024
A systematic review of pharmacogenetic testing to guide antipsychotic treatment. External Web Site Icon
Noushin Saadullah Khani et al. Nat Ment Health 2024 2(5) 616-626

More

About PGx PHGKB

PGx PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to medications....more

Content Summary

Common PGx Related Topics

Quick Links


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP